Sanders Morris Harris LLC grew its holdings in shares of Eli Lilly And Co (NYSE:LLY) by 33.8% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 10,208 shares of the company’s stock after buying an additional 2,578 shares during the quarter. Sanders Morris Harris LLC’s holdings in Eli Lilly And Co were worth $1,518,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. Public Employees Retirement Association of Colorado raised its holdings in shares of Eli Lilly And Co by 3.6% during the first quarter. Public Employees Retirement Association of Colorado now owns 163,830 shares of the company’s stock worth $22,726,000 after purchasing an additional 5,769 shares during the period. Skandinaviska Enskilda Banken AB publ boosted its position in shares of Eli Lilly And Co by 43.9% during the 1st quarter. Skandinaviska Enskilda Banken AB publ now owns 645,918 shares of the company’s stock valued at $89,601,000 after purchasing an additional 196,916 shares in the last quarter. Loomis Sayles & Co. L P boosted its holdings in shares of Eli Lilly And Co by 67.9% in the first quarter. Loomis Sayles & Co. L P now owns 7,954 shares of the company’s stock worth $1,103,000 after buying an additional 3,217 shares during the period. APG Asset Management N.V. lifted its position in shares of Eli Lilly And Co by 202.1% in the first quarter. APG Asset Management N.V. now owns 1,046,415 shares of the company’s stock worth $145,159,000 after purchasing an additional 699,987 shares in the last quarter. Finally, Procyon Private Wealth Partners LLC lifted its position in shares of Eli Lilly And Co by 5.3% in the first quarter. Procyon Private Wealth Partners LLC now owns 2,363 shares of the company’s stock worth $328,000 after purchasing an additional 118 shares in the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

In other news, SVP Melissa S. Barnes sold 5,000 shares of the business’s stock in a transaction on Tuesday, September 8th. The shares were sold at an average price of $151.01, for a total transaction of $755,050.00. Following the sale, the senior vice president now directly owns 23,580 shares of the company’s stock, valued at $3,560,815.80. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 0.09% of the stock is owned by insiders.

Shares of LLY stock traded down $0.66 during trading hours on Friday, hitting $146.12. The stock had a trading volume of 2,919,724 shares, compared to its average volume of 3,892,467. The stock has a market capitalization of $139.76 billion, a price-to-earnings ratio of 23.72, a PEG ratio of 1.35 and a beta of 0.19. Eli Lilly And Co has a one year low of $101.36 and a one year high of $170.75. The company has a debt-to-equity ratio of 3.53, a current ratio of 1.22 and a quick ratio of 0.94. The stock’s 50-day moving average price is $149.64 and its two-hundred day moving average price is $153.41.

Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings data on Thursday, July 30th. The company reported $1.89 EPS for the quarter, topping analysts’ consensus estimates of $1.58 by $0.31. The company had revenue of $5.50 billion during the quarter, compared to the consensus estimate of $5.77 billion. Eli Lilly And Co had a net margin of 24.48% and a return on equity of 183.80%. Eli Lilly And Co’s revenue for the quarter was down 2.4% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.50 earnings per share. As a group, equities research analysts predict that Eli Lilly And Co will post 7.31 earnings per share for the current fiscal year.

Several brokerages have recently issued reports on LLY. JPMorgan Chase & Co. raised their price objective on shares of Eli Lilly And Co from $190.00 to $200.00 and gave the stock an “overweight” rating in a research note on Friday. Mizuho boosted their price objective on Eli Lilly And Co from $155.00 to $164.00 and gave the stock a “neutral” rating in a report on Monday, June 29th. Berenberg Bank started coverage on Eli Lilly And Co in a research report on Tuesday, September 29th. They issued a “hold” rating and a $144.00 price objective for the company. ValuEngine downgraded Eli Lilly And Co from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Morgan Stanley upgraded Eli Lilly And Co from an “equal weight” rating to an “overweight” rating and upped their price objective for the stock from $149.55 to $176.00 in a research note on Thursday, September 3rd. They noted that the move was a valuation call. One research analyst has rated the stock with a sell rating, four have given a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $169.62.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

See Also: How is a buy-side analyst different from a sell-side analyst?

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.